A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients

References

1. ↵
   1. Tiepolt S,
   2. Hesse S,
   3. Patt M,
   4. Luthardt J,
   5. Schroeter ML,
   6. Hoffmann KT,
   7. et al.

   (2016) Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 43, 1700–1709.
2. ↵
   1. Alcolea D,
   2. Carmona-Iragui M,
   3. Suarez-Calvet M,
   4. Sanchez-Saudinos MB,
   5. Sala I,
   6. Anton-Aguirre S,
   7. et al.

   (2014) Relationship between beta-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer’s disease. J Alzheimers Dis 42, 157–167.
3. ↵
   1. Olsson B,
   2. Lautner R,
   3. Andreasson U,
   4. Ohrfelt A,
   5. Portelius E,
   6. Bjerke M,
   7. et al.

   (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease:a systematic review and meta-analysis. italic>Lancet Neurol 15, 673–684.
4. ↵
   1. Janelidze S,
   2. Hertze J,
   3. Zetterberg H,
   4. Landqvist Waldo M,
   5. Santillo A,
   6. Blennow K,
   7. et al.

   (2016) Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Ann Clin Transl Neurol 3, 12–20.
5. ↵
   1. Hellwig K,
   2. Kvartsberg H,
   3. Portelius E,
   4. Andreasson U,
   5. Oberstein TJ,
   6. Lewczuk P,
   7. et al.

   (2015) Neurogranin and YKL-40:independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease. Alzheimers Res Ther 7, 74.
6. ↵
   1. Wennstrom M,
   2. Surova Y,
   3. Hall S,
   4. Nilsson C,
   5. Minthon L,
   6. Hansson O,
   7. et al.

   (2015) The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies. PLoS One 10, e0135458.
7. ↵
   1. Craig-Schapiro R,
   2. Perrin RJ,
   3. Roe CM,
   4. Xiong C,
   5. Carter D,
   6. Cairns NJ,
   7. et al.

   (2010) YKL-40:a novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biol Psychiatry 68, 903–912.
8. ↵
   1. Zetterberg H,
   2. Skillback T,
   3. Mattsson N,
   4. Trojanowski JQ,
   5. Portelius E,
   6. Shaw LM,
   7. et al.

   (2016) Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol 73, 60–67.
9. ↵
   1. Li C,
   2. Pan W,
   3. Braunewell KH,
   4. Ames JB

   (2011) Structural analysis of Mg2+and Ca2+binding, myristoylation, and dimerization of the neuronal calcium sensor and visinin-like protein 1 (VILIP-1). J Biol Chem 286, 6354–6366.
10. ↵
    1. Ghosh A,
    2. Giese KP

    (2015) Calcium/calmodulin-dependent kinase II and Alzheimer’s disease. Mol Brain 8, 78.
11. ↵
    1. Tarawneh R,
    2. Head D,
    3. Allison S,
    4. Buckles V,
    5. Fagan AM,
    6. Ladenson JH,
    7. et al.

    (2015) Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. JAMA Neurol 72, 656–665.
12. ↵
    1. Mroczko B,
    2. Groblewska M,
    3. Zboch M,
    4. Muszynski P,
    5. Zajkowska A,
    6. Borawska R,
    7. et al.

    (2015) Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer’s disease. J Alzheimers Dis 43, 1031–1037.
13. ↵
    1. BabićLeko M,
    2. Borovečki F,
    3. Dejanović N,
    4. Hof PR,
    5. Šimić G

    (2016) Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer’s Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment. J Alzheimers Dis 50, 765–778.
14. ↵
    1. Luo X,
    2. Hou L,
    3. Shi H,
    4. Zhong X,
    5. Zhang Y,
    6. Zheng D,
    7. et al.

    (2013) CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer’s disease and dementia with Lewy bodies. J Neurochem 127, 681–690.
15. 1. Tarawneh R,
    2. D’Angelo G,
    3. Macy E,
    4. Xiong C,
    5. Carter D,
    6. Cairns NJ,
    7. et al.

    (2011) Visinin-like protein-1:diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 70, 274–285.
16. ↵
    1. Lee JM,
    2. Blennow K,
    3. Andreasen N,
    4. Laterza O,
    5. Modur V,
    6. Olander J,
    7. et al.

    (2008) The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem 54, 1617–1623.
17. ↵
    1. Kester MI,
    2. Teunissen CE,
    3. Sutphen C,
    4. Herries EM,
    5. Ladenson JH,
    6. Xiong C,
    7. et al.

    (2015) Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort. Alzheimers Res Ther 7, 59.
18. ↵
    1. Stroup DF,
    2. Berlin JA,
    3. Morton SC,
    4. Olkin I,
    5. Williamson GD,
    6. Rennie D,
    7. et al.

    (2000) Meta-analysis of observational studies in epidemiology:a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283, 2008–2012.
19. ↵
    1. Stang A

    (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25, 603–605.
20. ↵
    1. Stejskal D,
    2. Sporova L,
    3. Svestak M,
    4. Karpisek M

    (2011) Determination of serum visinin like protein-1 and its potential for the diagnosis of brain injury due to the stroke:a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 155, 263–268.
21. ↵
    1. Andrade-Moraes CH,
    2. Oliveira-Pinto AV,
    3. Castro-Fonseca E,
    4. da Silva CG,
    5. Guimaraes DM,
    6. Szczupak D,
    7. et al.

    (2013) Cell number changes in Alzheimer’s disease relate to dementia, not to plaques and tangles. Brain 136, 3738–3752.
22. ↵
    1. Tarawneh R,
    2. Lee JM,
    3. Ladenson JH,
    4. Morris JC,
    5. Holtzman DM

    (2012) CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 78, 709–719.
23. ↵
    1. Lin CW,
    2. Chang LC,
    3. Tseng GC,
    4. Kirkwood CM,
    5. Sibille EL,
    6. Sweet RA

    (2015) VSNL1 Co-Expression Networks in Aging Include Calcium Signaling, Synaptic Plasticity, and Alzheimer’s Disease Pathways. Front Psychiatry 6, 30.
24. ↵
    1. Zhang Z,
    2. Song M,
    3. Liu X,
    4. Su Kang S,
    5. Duong DM,
    6. Seyfried NT,
    7. et al.

    (2015) Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer’s disease. Nat Commun 6, 8762.